Products rabeprazole sodium
rabeprazole sodium Pre-clinical Completed 💤 Quiet Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Jan 1, 2011 → Aug 1, 2013
About rabeprazole sodium rabeprazole sodium is a pre-clinical stage product being developed by Eisai for Refractory Reflux Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01321567. Target conditions include Refractory Reflux Esophagitis.
Clinical Trials (7) NCT ID Phase Status Start Completion Indication NCT01264822 Pre-clinical Completed Jan 13, 2011 Nov 17, 2016 Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive NCT01321567 Pre-clinical Completed Jan 1, 2011 Aug 1, 2013 Refractory Reflux Esophagitis NCT00855361 Phase 1 Completed Jul 1, 2009 Dec 1, 2011 Gastroesophageal Reflux NCT00747695 Phase 1 Completed Mar 1, 2008 Sep 1, 2009 GERD NCT01286194 Pre-clinical Completed Apr 1, 2006 Jan 1, 2007 Frequent Heartburn NCT00236184 Phase 3 Completed Oct 1, 2005 Jun 1, 2008 Heartburn NCT00132496 Phase 2 Completed Aug 1, 2005 Jul 1, 2006 Gastroesophageal Reflux Disease
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3 Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules). Eisai Phase 1
Other Products from Eisai